-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

Benzinga·09/09/2026 18:08:44
Listen to the news
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.